Literature DB >> 31525073

Impact of Past Research Experience on Subsequent Trials: A Caution.

Miguel A Villarreal1, Jeremy J Wildfire1, Christine A Sorkness2, Peter J Gergen3, Cynthia M Visness1, Herman E Mitchell1.   

Abstract

Mesh：

Year:  2020        PMID： 31525073      PMCID： PMC6961745          DOI： 10.1164/rccm.201905-0926LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  8 in total

1.  Recruitment and retention strategies in longitudinal clinical studies with low-income populations.

Authors:  Lisa M Nicholson; Patricia M Schwirian; Elizabeth G Klein; Theresa Skybo; Lisa Murray-Johnson; Ihuoma Eneli; Bethany Boettner; Gina M French; Judith A Groner
Journal:  Contemp Clin Trials       Date:  2011-01-27       Impact factor: 2.226

2.  Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial.

Authors:  Stanley J Szefler; Herman Mitchell; Christine A Sorkness; Peter J Gergen; George T O'Connor; Wayne J Morgan; Meyer Kattan; Jacqueline A Pongracic; Stephen J Teach; Gordon R Bloomberg; Peyton A Eggleston; Rebecca S Gruchalla; Carolyn M Kercsmar; Andrew H Liu; Jeremy J Wildfire; Matthew D Curry; William W Busse
Journal:  Lancet       Date:  2008-09-20       Impact factor: 79.321

3.  Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.

Authors:  Stephen J Teach; Michelle A Gill; Alkis Togias; Christine A Sorkness; Samuel J Arbes; Agustin Calatroni; Jeremy J Wildfire; Peter J Gergen; Robyn T Cohen; Jacqueline A Pongracic; Carolyn M Kercsmar; Gurjit K Khurana Hershey; Rebecca S Gruchalla; Andrew H Liu; Edward M Zoratti; Meyer Kattan; Kristine A Grindle; James E Gern; William W Busse; Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2015-10-27       Impact factor: 10.793

4.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.

Authors:  William W Busse; Wayne J Morgan; Peter J Gergen; Herman E Mitchell; James E Gern; Andrew H Liu; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Jacqueline A Pongracic; James F Chmiel; Suzanne F Steinbach; Agustin Calatroni; Alkis Togias; Katherine M Thompson; Stanley J Szefler; Christine A Sorkness
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

5.  A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study.

Authors:  R Evans; P J Gergen; H Mitchell; M Kattan; C Kercsmar; E Crain; J Anderson; P Eggleston; F J Malveaux; H J Wedner
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

6.  Asthma phenotypes in inner-city children.

Authors:  Edward M Zoratti; Rebecca Z Krouse; Denise C Babineau; Jacqueline A Pongracic; George T O'Connor; Robert A Wood; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Steven M Sigelman; Peter J Gergen; Alkis Togias; Cynthia M Visness; William W Busse; Andrew H Liu
Journal:  J Allergy Clin Immunol       Date:  2016-10       Impact factor: 10.793

7.  Design and methods of the National Cooperative Inner-City Asthma Study.

Authors:  H Mitchell; Y Senturia; P Gergen; D Baker; C Joseph; K McNiff-Mortimer; H J Wedner; E Crain; P Eggleston; R Evans; M Kattan; C Kercsmar; F Leickly; F Malveaux; E Smartt; K Weiss
Journal:  Pediatr Pulmonol       Date:  1997-10

8.  Validation of the maximum symptom day among children with asthma.

Authors:  Tianshi David Wu; Matthew Perzanowski; Roger D Peng; Robert A Wise; Susan Balcer-Whaley; Michelle Newman; Amparito Cunningham; Wanda Phipatanakul; Elizabeth C Matsui; Meredith C McCormack
Journal:  J Allergy Clin Immunol       Date:  2018-10-19       Impact factor: 10.793
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.